Kenneth R. Carson, MD
Articles
April 2nd 2024
Adjusting Starting Points for Initial Price Offers: The Example of Ibrutinib
Jason B. Gibbons, PhD Charles L. Bennett, MD, PhD, MPP Kenneth R. Carson, MD Gerard F. Anderson, PhD
Ibrutinib has been selected for Medicare price negotiation under the Inflation Reduction Act. The authors summarize the House Oversight Committee investigation to be considered by CMS during the price negotiation process.
January 19th 2012
Economic Evaluation of Plerixafor for Stem Cell Mobilization
Steven M. Kymes, PhD Iskra Pusic, MD Dennis L. Lambert, PhD Martin Gregory, BA Kenneth R. Carson, MD John F. DiPersio, MD, PhD
Use of granulocyte colony-stimulating factor plus plerixafor for stem cell mobilization is cost-effective in pretreated patients with non-Hodgkin lymphoma.
Latest Updated Articles
Published: August 18th 2025 | Updated: August 25th 2025
Conditional Economic Incentives Could Be Effective in Improving Adherence to Long-Acting PrEP in Transgender Adults
Published: August 19th 2025 | Updated: August 22nd 2025
Semaglutide Not Associated With Increased Risk of Eye Disorders
Published: June 6th 2025 | Updated: August 18th 2025
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
Published: June 27th 2025 | Updated: July 1st 2025
Report Reveals Mounting Burdens of Drug Shortages on US Health System
Published: February 20th 2025 | Updated: February 21st 2025
Managed Care Reflections: Insights From Richard J. Gilfillan, MD; and Donald M. Berwick, MD, MPP
Published: January 16th 2025 | Updated: January 29th 2025
FDA Proposal Aims to Reduce Smoking Addiction and SCLC Cases
